This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myrexis Presents Data On Cancer Metabolism Inhibitor At 22nd EORTC/NCI/AACR Symposium

SALT LAKE CITY, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany. The presentations further demonstrate best-in-class potential for the Company's cancer metabolism inhibitor, MPC-9528, which has previously been shown to cause profound and durable tumor regressions across multiple tumor types. 

MPC-9528 exhibited superior potency in enzymatic, cellular, and mouse xenograft models, compared to other small molecules that target the same metabolic enzyme. Furthermore, MPC-9528 demonstrated synergy with poly(ADP-ribose) polymerase (PARP) inhibitors, which are involved in DNA repair and are active against tumors with genetic deficiency for BRCA.

"Based upon the data we've collected to date, we remain confident in the best-in-class profile of our cancer metabolism inhibitor," said Robert Carlson, Ph.D., Vice President and Head of Research at Myrexis. "We are encouraged by the superior potency, therapeutic index and potential for broad therapeutic application of our compound. We are also excited about the opportunities for combination of MPC-9528 with other chemotherapeutics to achieve synergistic anti-tumor activity."

MPC-9528 inhibits cancer metabolism by targeting nicotinamide phosphoribosyltransferase, or Nampt, a key enzyme in the primary pathway for producing nicotinamide adenine dinucleotide (NAD), which is required by all cells to carry out normal functions such as glucose metabolism, DNA repair and gene expression. By exploiting cancer cells' increased requirements for NAD, MPC-9528 is able to selectively inhibit the growth of tumor cells.

In a poster titled, "Anti-Tumor Activity of MPC-9528, GMX1778 and APO866: Nampt Inhibitors of Three Different Structural Classes," Myrexis showed that MPC-9528 was the most potent inhibitor of human Nampt and caused the most efficient NAD depletion and cell death in cancer cell lines in vitro. In addition, MPC-9528 also demonstrated the greatest in vivo potency in pre-clinical models.

Myrexis also presented a poster titled, "The Nampt Inhibitor MPC-9528 and the PARP Inhibitor Olaparib Synergize in Killing BRCA-Deficient Cancer Cell Lines." The Company demonstrated that MPC-9528 and oliparib inhibit PARP by distinct mechanisms, and as a result, are strongly synergistic against BRCA1 (-/-) and BRCA2 (-/-) cancer cell lines. Specifically, sub-lethal doses of MPC-9528 enhanced the potency of olaparib in a BRCA-dependent manner.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs